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ABSTRACT 
 
Objective: The objective of this selective EBM review is to determine whether or not 
methylergometrine is more effective than other uterotonic agents in preventing postpartum 
hemorrhage during the third stage of labor. 
 
Study Design: Review of two randomized controlled trials (RCTs) published in 2004 and 2009, 
and one prospective study published in 2006. 
 
Data Sources: Each article used was published in English and found using PubMed and 
Medline.  The studies compared the efficacy of methylergometrine against uterotonic agents, 
specifically oxytocin and misoprostol. 
 
Outcomes Measured: The efficacy of methylergometrine was measured via the incidence of 
postpartum hemorrhage despite the use of prophylactic medication and adverse effects of 
medications. 
 
Results: Vimala et al (2004) found that methylergometrine and misoprostol were equally 
effective at decreasing the amount of blood loss [170±42ml vs. 185±56ml; p >0.05], as well as in 
terms of adverse side effects, specifically nausea [13.3% vs. 6.6%; p >0.05].  Singh et al (2009) 
found that methylergometrine was less effective compared to oxytocin in reducing the mean 
blood loss during the third stage of labor [223.48ml vs. 154.73ml; p <0.01].  While Fujimoto et 
al (2006) also noted that methylergometrine was more likely increase incidences of postpartum 
hemorrhage than oxytocin [18.6% vs. 7.3%; OR = 0.31], no differences in resultant adverse side 
effects were found [2.8% vs. 1.2%]. 
 
Conclusions: Due to the limitations of the studies with regards to the use of methylergometrine 
compared to other uterotonic agents, its efficacy over these drugs remains inconclusive.  
However, methylergometrine was not shown to produce more adverse side effects than standard 
of care uterotonic agents oxytocin and misoprostol.  
 
Key Words: Methylergometrine, oxytocin, misoprostol, postpartum hemorrhage, third stage 
labor. 
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INTRODUCTION 
 Postpartum hemorrhage, defined as when a vaginal delivery results in greater than 500ml 
of blood loss, is a major cause of maternal death.  While it can be attributed to lacerations 
sustained during childbirth, retention of products of conception or placental tissue, or defects in 
blood coagulation, uterine atony is the preeminent cause of hemorrhage after delivery.  
Following the vaginal birth of an infant, the myometrium is responsible for contracting in order 
to reduce uterine size and help clamp the vasculature where the placenta implants.  However, if 
the uterus becomes atonic, the myometrial fibers fail to constrict and continued bleeding from 
uterine vessels occurs, which can result in excessive blood loss.  Postpartum hemorrhage is the 
foremost cause of pregnancy-related mortality in developing countries and is ranked third in the 
United States
1
, with 11.8% of maternal deaths in the US from 2006-2010 resulting from 
hemorrhage.
2
 
 Considering the potentially life-threatening consequences of labor complications, the 
appropriate treatment with regards to postpartum hemorrhage is important to both practitioners 
and patients.  Since physician assistants are involved in the delivery of infants, knowledge of the 
management of labor complications is essential.  In all but four states, the extent of obstetrical 
care a PA can provide is determined by the supervising physician and hospital regulations.  This 
means that PAs can be involved in labor and delivery,
3
 where recognizing and appropriately 
treating postpartum hemorrhage is vital. 
 In 2012, there were 3,952,841 live births in the US.
4
  Though data on the national 
expenditure in cases of maternal hemorrhage are not available, a study limited to California 
hospitals performed by UCLA calculated that there is an increased cost of $3,000 per patient.  If 
severe hemorrhage necessitates hysterectomy, there is an increased cost of $6,403.
5
  Statistics are 
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not available for the number of health care visits attributed to postpartum hemorrhage each year, 
but another study based in California found that 2.4% of live births were associated with 
postpartum hemorrhage.
6
 
 In spite of identifying the cause and risk factors for most postpartum hemorrhage, it is 
still difficult to determine which patient will develop hemorrhage.  Uterine atony can be 
attributed to prolonged labor, undue manipulation or dysfunction of the uterus, uterine fibroids, 
augmented labor via oxytocin, or use of general anesthesia.  Women whose uterus has undergone 
greater distention due to multiple gestation or polyhydramnios are also prone to atony.
1
  
Prophylactic administration of uterotonic agents has been implemented to prevent hemorrhage, 
but this method is not infallible, as evidenced by maternal mortality rates.  Uterotonic agents are 
responsible for stimulating contractions of the uterus, namely in the form of oxytocin, 
methylergometrine, or misoprostol.
7
  These medications are generally administered during the 
third stage of labor, or following delivery of the anterior shoulder.
8,9,10 
 Currently, oxytocin and misoprostol are uterotonic agents used for the prevention of 
postpartum hemorrhage during the third stage of labor.  The gold standard treatment for 
postpartum hemorrhage is administration of intravenous oxytocin.  Oxytocin has been found to 
most effectively minimize the amount of blood loss with the least amount of side effects.  
Another option for treatment also includes sublingual administration of misoprostol, which is 
effective but associated with more side effects.  Although misoprostol is not first line in the 
United States, its use has been noted specifically in low resource areas where skilled 
practitioners and high tech equipment is not as readily available.  Due to these factors, it has 
been noted to be a standard of care medication in prevention of postpartum hemorrhage.  Since it 
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is provided as a sublingual tablet, it does not require training to administer.  Additionally, unlike 
oxytocin, it does not require refrigeration to maintain its potency.
1,7
 
 In the past, methylergometrine has been used as an adjunct therapy if oxytocin has not 
been effective in stopping bleeding in cases of postpartum hemorrhage.
1
  Methylergometrine, 
also known as methylergonovine, is an ergot derivative that presents as another one option for 
the active management due to its uterotonic properties.  It is available as an injection (IV or IM) 
as well as an oral tablet.
11
  The effects of this drug also last for approximately 2-4 hours, which is 
longer than oxytocin that lasts about 15-30 minutes, and misoprostol that lasts about 75 minutes.
7 
OBJECTIVE 
 The objective of this systematic review is to determine whether or not methylergometrine 
is more effective than other uterotonic agents for the active management of the third stage of 
labor. 
METHODS 
 This review examined two randomized controlled trials and one prospective study, all of 
which examined pregnant women at full term with a single uterine pregnancy who were in labor.  
The intervention used was methylergometrine, which was compared to the experimental group 
who received either oxytocin or misoprostol.  Though the studies used different outcomes, the 
intention was to determine the efficacy of methylergometrine compared to other uterotonic 
agents.  These outcomes were measured by mean amount of blood loss, incidence of postpartum 
hemorrhage, and incidence of adverse side effects. 
 In order to find articles for this review, key words utilized include methylergometrine, 
oxytocin, misoprostol, postpartum hemorrhage, and third stage of labor.  All articles used were 
published in English and found via searches on Medline and PubMed.  These articles were then 
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selected by the author based upon their relevance to the stated clinical question and whether or 
not outcomes were applicable to patients.  The inclusion criteria included randomized controlled 
trials and one prospective study published after the year 2000 that studied full term pregnant 
females with a single uterine pregnancy in the third stage of labor.  Pregnant women who had to 
undergo a cesarean section, induced labor, preterm labor, or multiple gestation were excluded.  
Summary statistics used were means, standard deviations, p-values, and odds ratios. 
Table 1: Demographics and Characteristics of Included Studies 
Study Type # 
Pts 
Age 
(Years) 
Inclusion 
Criteria 
Exclusion Criteria W/D Inter-
ventions 
Fuji-
moto
8
 
(2006) 
Prosp-
ective 
Study 
438 Not 
specified 
Pregnant 
women in 
spontaneous 
onset of 
labor, 
healthy, 
single 
gestation 
Previous c-section, 
history of antepartum 
hemorrhage or 
postpartum hemorrhage 
in a previous pregnancy, 
or contraindication for 
receiving uterotonic 
drugs. 
0 Methylerg-
ometrine 
200 μg (IV) 
Singh
9
 
(2009) 
RCT 300 Not 
specified 
Pregnant 
women ≥37 
weeks of 
gestation in 
spontaneous 
or induced 
onset of labor 
with healthy, 
single 
gestation 
Known hyper-sensitivity/ 
contraindication to 
prostaglandins, 
intrauterine fetal demise, 
antepartum hemorrhage, 
multiple pregnancy, 
malpresentation, cardiac 
disease, Rh
-
 mother, 
hypersensitive disorders, 
hemoglobin < 7g/dl, or 
use of oxytoxics until the 
second stage of labor. 
0 Methylerg-
ometrine 
200 μg (IV) 
Vima-
la
10
 
(2004) 
RCT 120 Not 
specified 
Pregnant 
women ≥37 
weeks of 
gestation 
with 
spontaneous 
onset of labor 
Use of oxytoxin to 
augment or induce labor, 
c-section deliveries, 
grand multipara (parity 
>5), gestation <37 weeks, 
multiple gestation, 
pregnancy-induced 
hypertension, hemoglobin 
concentration <8 gm/dl, 
or known hyper-
sensitivity to 
prostaglandins 
0 Methylerg-
ometrine 
200 μg (IV) 
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OUTCOMES MEASURED 
 The outcomes measured were the incidence of postpartum hemorrhage despite the use of 
prophylactic uterotonic agents as well as adverse effects of medication use.  This was determined 
by the difference of mean blood loss and whether or not the values were significant, as well as 
clinical cases of postpartum hemorrhage.  This allowed for determination as to whether or not 
each agent was better at preventing significant amounts of blood lost.  There was also analysis 
regarding the adverse side effects of the medications.  Patients reported several side effects, 
including nausea, vomiting, and headache, though this review focused specifically on incidence 
of subsequent nausea experienced by patients.
8,9,10 
RESULTS 
 The two randomized controlled trials and one prospective study used in this review all 
compare the effectiveness of methylergometrine compared to another uterotonic agent, either 
oxytocin or misoprostol.  Efficacy of these medications was evaluated through incidence of 
postpartum hemorrhage and adverse side effects of medication.  The inclusion and exclusion 
criteria were all comparable in these studies (Table 1), and all patients that entered the trial were 
accounted for at the conclusion.
8,9,10
 
 In the randomized controlled trial performed by Vimala et al, 120 pregnant women were 
randomized into two treatment groups.  Use of IV methylergometrine was compared to 
sublingual misoprostol during the third stage of labor.  Both treatment groups had similar results 
with regards to estimated blood loss and incidence of post partum hemorrhage, and the 
differences in the data were not found to be statistically significant.  With methylergometrine, 
there were no cases of postpartum hemorrhage, whereas there were two cases after 
administration of misoprostol amounting to 3.3% (p >0.05, CI = 90%) (Table 2).
10
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Table 2: Methylergometrine vs. misoprostol during the third stage of labor (Vimala et al, 2004)
10 
 Methylergometrine  Misoprostol P value 
Estimated Blood Loss (ml) 170 ± 42 185 ± 56 p > 0.05 
Blood Loss ≥500ml 0% 3.3% p > 0.05 
Nausea 13.3% 6.6% p > 0.05 
 
 In terms of adverse side effects, methylergometrine and misoprostol were once again 
comparable with 13.3% and 6.6% incidences, respectively (p >0.05, CI = 90%) (Table 2).  This 
study showed that overall, there were no noteworthy differences between using 
methylergometrine and misoprostol in terms of drug efficacy, and the discrepancies can be 
attributed to random variance (Table 2).  This suggests that the two are equally effective in the 
management of postpartum hemorrhage during the third stage of labor.  As seen in Tables 3, for 
every 30 participants who were administered methylergometrine, there was one fewer incidence 
of postpartum hemorrhage compared to those who were given misoprostol.  However, for every 
15 patients treated with methylergometrine, one additional would experience nausea (Table 4).
10 
Table 3: Methylergometrine vs. misoprostol comparison of incidence of postpartum hemorrhage 
(Vimala et al, 2004)
10 
More episodes of postpartum 
hemorrhage 
Relative Risk 
Reduction 
(RRR) 
Absolute Risk 
Reduction (ARR) 
Number 
Needed to 
Treat (NNT) 
Misoprostol: 
Control Event 
Rate (CER) 
Methylergometrine: 
Experimental Event 
Rate (EER) 
EER – CER 
     CER 
EER – CER 1/ARR 
0.033 0 -1 -0.033 -30 
 
Table 4: Methylergometrine vs. misoprostol comparison of incidence of nausea (Vimala et al, 
2004)
10
 
More episodes of nausea due to 
medication 
Relative Risk 
Increase (RRI) 
Absolute Risk 
Increase (ARI) 
Number 
Needed to 
Harm (NNH) 
Misoprostol: 
Control Event 
Rate (CER) 
Methylergometrine: 
Experimental Event 
Rate (EER) 
EER – CER 
     CER 
EER – CER 1/ARI 
0.066 0.133 1.015 0.067 15 
 
 Singh et al performed a randomized controlled trial that evaluated IV methylergometrine 
against IV oxytocin, with 75 women recruited for each group.  This study showed that oxytocin 
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was more effective than methylergometrine at minimizing blood loss by measuring the mean 
amount of blood loss after delivery.  For those given oxytocin, blood loss was about 154.73ml, 
compared to methylergometrine where blood loss was about 223.48ml (p <0.01; CI = 0.95) 
(Table 5).
9 
Table 5: Methylergometrine vs. oxytocin during the third stage of labor (Singh et al, 2009)
9 
 Methylergometrine  Oxytocin P value 
Mean Blood Loss (ml) 223.48 154.73 p <0.01 
 
 Although the study performed by the Singh et al did not include an analysis as to whether 
or not incidences of postpartum hemorrhage were statistically significant, the data indicated that 
for every 38 patients who were given prophylactic methylergometrine, there was one more 
incidence of postpartum hemorrhage than those who were given prophylactic oxytocin (Table 6).  
It was found that the only cases of blood loss exceeding 500ml were in those given 
methylergometrine, with no incidence of postpartum hemorrhage in the group given oxytocin.
9 
Table 6: Methylergometrine vs. oxytocin comparison of incidence of postpartum hemorrhage 
(Singh et al, 2009)
9
 
More episodes of postpartum 
hemorrhage due to medication 
Relative Risk 
Increase (RRI) 
Absolute Risk 
Increase (ARI) 
Number 
Needed to 
Harm (NNH) 
Oxytocin: 
Control Event 
Rate (CER) 
Methylergometrine: 
Experimental Event 
Rate (EER) 
EER – CER 
     CER 
EER – CER 1/ARI 
0 0.027 N/A 0.027 38 
 
 In the prospective study carried out by Fujimoto et al, use of prophylactic IV 
methylergometrine and IV oxytocin were examined.  Although there were reported incidences of 
postpartum hemorrhage with use of both drugs, methylergometrine administration resulted in 
more cases.  There was noted to be a statistically significant increase in incidence of postpartum 
hemorrhage when methylergometrine was used compared to oxytocin at 18.6% and 7.3%, 
respectively (OR 0.31, CI = 95%) (Table 7).
8 
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Table 7: Methylergometrine vs. oxytocin during the third stage of labor (Fujimoto et al, 2006)
8 
 Methylergometrine  Oxytocin Odds Ratio 
Blood Loss ≥500ml 18.6%% 7.3% 0.31 
Nausea 2.8% 1.2% -- 
 
 Considering the results from the Fujimoto et al study, it can be established that for every 
8 participants who was administered methylergometrine, there was one more incidence of 
postpartum hemorrhage compared to those given oxytocin (Table 8).  Furthermore, for every 63 
patients treated with methylergometrine, one additional patient would also experience nausea 
(Table 9).  Though there is not a prominent difference in adverse side effects, the ability of 
oxytocin to minimizing postpartum hemorrhage was shown to be greater.
9 
Table 8: Methylergometrine vs. oxytocin comparison of incidence of postpartum hemorrhage 
(Fujimoto et al, 2006)
8
 
More episodes of postpartum 
hemorrhage 
Relative Risk 
Increase (RRI) 
Absolute Risk 
Increase (ARI) 
Number 
Needed to 
Harm (NNH) 
Oxytocin: 
Control Event 
Rate (CER) 
Methylergometrine: 
Experimental Event 
Rate (EER) 
EER – CER 
     CER 
EER – CER 1/ARI 
0.073 0.186 1.55 0.133 8 
 
Table 9: Methylergometrine vs. oxytocin comparison of incidence of nausea (Fujimoto et al, 
2006)
8
 
More episodes of nausea due to 
medication 
Relative Risk 
Increase (RRI) 
Absolute Risk 
Increase (ARI) 
Number 
Needed to 
Harm (NNH) 
Oxytocin: 
Control Event 
Rate (CER) 
Methylergometrine: 
Experimental Event 
Rate (EER) 
EER – CER 
     CER 
EER – CER 1/ARI 
0.012 0.028 1.33 0.016 63 
 
DISCUSSION 
 Though studies by Singh et al and Fujimoto et al came to the conclusion that oxytocin 
was more effective than methylergometrine in preventing postpartum hemorrhage, the contrast in 
the numbers needed to harm indicates that there is an issue with consistency in the underlying 
data. 
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 While the availability of methylergometrine is not an issue in the United States, it can be 
in low resource countries.  Much like oxytocin, methylergometrine is given intravenously, which 
means that training is required for those who are tasked with administering it during labor.
1
  
Though the studies utilized in this review did not address intramuscular or oral 
methylergometrine, these are also options that are available.  While injectable forms must be 
refrigerated and shield against light, the oral tablet can be stored at room temperature, potentially 
making it more accessible.
11 
 This drug is used specifically for managing issues related to postpartum hemorrhage, 
such as uterine atony and failure of the uterus to return to its normal size after the placenta is 
delivered.  As an ergot derivative, it works by increasing and sustaining smooth muscle 
contraction in the uterus.
11
  The use of methylergometrine is contraindicated in patients with 
hypertension,
1
 and consequently preeclampsia and eclampsia.
7
  It also should not be used in 
those with coronary heart disease, as it increases the risk of vasospasm and thus myocardial 
ischemia.  Such vasoconstriction can also occur in the peripheral vascular system and lead to 
ischemia and gangrene, known as ergotism where there is an overdose or chronic use of the drug.  
This ergot toxicity is possible if methylergometrine is used in conjunction with potent CYP3A4 
inhibitors as well, so it is not recommended if a patient is also taking macrolides, azole 
antifungals, or protease inhibitors.
11 
 There were limitations with this review due to inadequate randomized controlled trials 
performed with regards to the clinical question.  While standard of care uterotonic agents were 
compared to methylergometrine, another randomized controlled trial would have provided more 
valuable information than a prospective study.  Moreover, all of the studies used had small 
sample sizes.  The treatment groups ranged from 60-82 patients, which does not provide a great 
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deal of information.  Due to this, there was quite a bit of variation in the data from one study to 
the next.
8,9,10 
CONCLUSION 
 After reviewing the data from the three studies, it is inconclusive as to whether or not 
methylergometrine is more effective than other uterotonic agents.  Though both studies that 
compared methylergometrine to oxytocin showed that its use resulted in more incidence of 
postpartum hemorrhage, the underlying numbers showed quite a bit of discrepancy.  The 
numbers needed to harm in the Fujimoto study were far more drastic at one in every eight 
patients resulting in postpartum hemorrhage (Table 8), as opposed to the Singh study where one 
in every thirty eight had that outcome (Table 6).
8,9
  When comparing methylergometrine to 
misoprostol in a randomized controlled study, the two appeared to be equivalent, but since it was 
only one study, more evidence would be necessary to definitively come to such a conclusion.
10 
 Future studies are indicated in order to determine whether or not methylergometrine is a 
viable option for prevention of postpartum hemorrhage.  Comparing oral methylergometrine with 
other uterotonic agents may be a more valuable study, especially since it can be more easily used 
and stored in countries with low resources where the gold standard treatment is not a viable 
option. 
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